CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. — fact timeline

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. issued 2,790,340 shares of common stock of warrant to holders of existing warrants for cash exercise of existing warrants at $3.75 per share for aggregate gross proceeds of approximately $4.2 million.

“On October 29, 2025, Creative Medical Technology Holdings, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with the holders (the “Holders”) of warrants to purchase an aggregate of 1,116,136 shares of the Company’s common stock originally issued on March 6, 2025 (collectively, the “Existing Warrants”), pursuant to which the Holders agreed to exercise the Existing Warrants at their current exercise price of $3.75 per share, in exchange for the Company’s agreement to issue the Holders new warrants to purchase an aggregate of 2,790,340 shares of common stock (the “Inducement Warrants”).”

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. received a nasdaq deficiency notice notice regarding other (rules 5608(b)(1), 5608(b)(2)).

“April 8, 2025, the Company received a letter from Nasdaq stating that because the Company failed to timely adopt the Policy as required by Listing Rule 5608(b)(1), and failed to disclose the Policy in its Form 10-K for the fiscal years ended December 31, 2023 or December 31, 2024 (prior to its amendment), the Company previously did not comply with Listing Rule 5608(b)(2). However, in the letter, Nasdaq further informed the Company that it is currently in compliance with Nasdaq Listing Rules, and the matter raised by Nasdaq in the letter is now closed.”

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.: Increased authorized common shares from 5,000,000 to 25,000,000 (effective 2024-12-19).

“On December 19, 2024, the stockholders of Creative Medical Technology Holdings, Inc. (the “Company”) approved an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock from 5,000,000 to 25,000,000.”

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shareholders approved Ratification of the appointment of Haynie & Company to serve as the Company's independent registered public accountants at the 2023-12-20 meeting.

“For Against Abstain Broker Non-Votes 751,848 23,485 1,649 N/A”

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shareholders approved Approval of the compensation of the Company's named executive officers at the 2023-12-20 meeting.

“For Against Abstain Broker Non-Votes 169,498 90,645 1,077 515,762”

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shareholders approved Election of five director nominees to the Board at the 2023-12-20 meeting.

“Timothy Warbington 237,163 24,057 Donald Dickerson 237,192 24,028 Michael H. Finger 234,462 26,758 Susan Snow 237,729 23,491 Bruce S. Urdang, Esq. 235,547 25,673”

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.: Reverse stock split at 1-for-10 ratio and reduction of authorized common stock from 50 million to 5 million via Certificate of Change filed with Nevada Secretary of State (effective 2023-06-12).

“Following the approval of the Board of Directors of Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), the Company is effecting a reverse stock split of its common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-10 (the “Reverse Stock Split”). The Reverse Stock Split will be effected pursuant to a Certificate of Change Pursuant to NRS 78.209 (the “Certificate”) that was filed with the Secretary of State of the State of Nevada on June 1, 2023. In addition to effecting the Reverse Stock Split, the filing of the Certificate reduces the authorized number of shares of the Company’s Common Stock from 50 million to five million.”

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shareholders approved Ratification of appointment of Haynie & Company as independent registered public accountants at the 2022-12-19 meeting.

“Proposal IV - The ratification of the appointment of Haynie & Company was approved as follows: For Against Abstain Broker Non-Votes 7,690,484 144,871 20,579 N/A”

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shareholders approved Advisory vote on frequency of executive compensation votes at the 2022-12-19 meeting.

“Proposal III – Holding an advisory vote on executive compensation on an annual basis was approved as follows: One Year Two Years Three Years Abstain Broker Non-Votes 2,854,354 33,493 116,755 33,046 4,818,286”

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shareholders approved Approval of the compensation of the Company's named executive officers at the 2022-12-19 meeting.

“Proposal II - The compensation of the Company’s named executive officers was approved as follows: For Against Abstain Broker Non-Votes 2,422,079 588,661 26,908 4,818,286”

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shareholders approved Election of the five director nominees named in the Proxy Statement at the 2022-12-19 meeting.

“The five director nominees were all elected to the Board as follows: Director For Withhold Timothy Warbington 2,694,252 343,196 Donald Dickerson 2,693,855 343,793 Michael H. Finger 2,675,852 361,796 Susan Snow 2,690,084 347,564 Bruce S. Urdang, Esq. 2,677,918 359,730”

Bruce S. Urdang was appointed as Director at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..

“Michael H. Finger, Susan Snow and Bruce S. Urdang were appointed to serve as directors of the Company.”

Susan Snow was appointed as Director at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..

“Michael H. Finger, Susan Snow and Bruce S. Urdang were appointed to serve as directors of the Company.”

Michael H. Finger was appointed as Director at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..

“Michael H. Finger, Susan Snow and Bruce S. Urdang were appointed to serve as directors of the Company.”

Amit Patel resigned as Director at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..

“Drs. Thomas Ichim and Amit Patel resigned as directors of the Company;”

Thomas Ichim resigned as Director at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..

“Drs. Thomas Ichim and Amit Patel resigned as directors of the Company;”